"Antibodies, Viral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Immunoglobulins produced in response to VIRAL ANTIGENS.
| Descriptor ID |
D000914
|
| MeSH Number(s) |
D12.776.124.486.485.114.254 D12.776.124.790.651.114.254 D12.776.377.715.548.114.254
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Viral".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Viral".
This graph shows the total number of publications written about "Antibodies, Viral" by people in this website by year, and whether "Antibodies, Viral" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 4 | 1 | 5 |
| 1996 | 5 | 8 | 13 |
| 1997 | 2 | 5 | 7 |
| 1998 | 3 | 9 | 12 |
| 1999 | 3 | 8 | 11 |
| 2000 | 1 | 6 | 7 |
| 2001 | 5 | 6 | 11 |
| 2002 | 4 | 8 | 12 |
| 2003 | 6 | 6 | 12 |
| 2004 | 3 | 7 | 10 |
| 2005 | 6 | 7 | 13 |
| 2006 | 5 | 2 | 7 |
| 2007 | 1 | 5 | 6 |
| 2008 | 5 | 11 | 16 |
| 2009 | 4 | 9 | 13 |
| 2010 | 2 | 6 | 8 |
| 2011 | 5 | 9 | 14 |
| 2012 | 10 | 12 | 22 |
| 2013 | 14 | 6 | 20 |
| 2014 | 12 | 12 | 24 |
| 2015 | 21 | 10 | 31 |
| 2016 | 12 | 15 | 27 |
| 2017 | 13 | 11 | 24 |
| 2018 | 18 | 12 | 30 |
| 2019 | 13 | 10 | 23 |
| 2020 | 24 | 16 | 40 |
| 2021 | 25 | 30 | 55 |
| 2022 | 4 | 47 | 51 |
| 2023 | 4 | 43 | 47 |
| 2024 | 22 | 13 | 35 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Viral" by people in Profiles.
-
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost. Nat Commun. 2025 Jan 17; 16(1):759.
-
Risk reduction in SARS-CoV-2 infection and reinfection conferred by humoral antibody levels among essential workers during Omicron predominance. PLoS One. 2024; 19(12):e0306953.
-
Optimizing immunogenicity and product presentation of a SARS-CoV-2 subunit vaccine composition: effects of delivery route, heterologous regimens with self-amplifying RNA vaccines, and lyophilization. Front Immunol. 2024; 15:1480976.
-
Correlation of Genogroup I, Genotype 1 (GI.1) Norovirus Neutralizing Antibody Levels With GI.1 Histo-Blood Group Antigen-Blocking Antibody Levels. J Infect Dis. 2024 Dec 16; 230(6):1376-1379.
-
Protective threshold of a potent neutralizing Zika virus monoclonal antibody in rhesus macaques. J Virol. 2024 Dec 17; 98(12):e0142924.
-
SARS-CoV-2 XBB.1.5 mRNA booster vaccination elicits limited mucosal immunity. Sci Transl Med. 2024 Oct 23; 16(770):eadp8920.
-
Determination of T cell response against XBB variants in adults who received either monovalent wild-type inactivated whole virus or mRNA vaccine or bivalent WT/BA.4-5 COVID-19 mRNA vaccine as the additional booster. Int J Infect Dis. 2024 Dec; 149:107271.
-
Utility of ISARIC 4C Mortality Score, Vaccination History, and Anti-S Antibody Titre in Predicting Risk of Severe COVID-19. Viruses. 2024 Oct 12; 16(10).
-
Discovery and characterization of a pan-betacoronavirus S2-binding antibody. Structure. 2024 Nov 07; 32(11):1893-1909.e11.
-
Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages. Emerg Microbes Infect. 2024 Dec; 13(1):2402880.